Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · IEX Real-Time Price · USD
4.100
+0.060 (1.49%)
At close: Jul 2, 2024, 4:00 PM
4.180
+0.080 (1.95%)
After-hours: Jul 2, 2024, 7:02 PM EDT
Xenetic Biosciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Xenetic Biosciences.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for XBIO.
Recommendation Trends
Rating | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +875.61% | Apr 11, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $40 | Strong Buy | Maintains | $50 → $40 | +875.61% | May 2, 2022 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $50 | Strong Buy | Maintains | $20 → $50 | +1,119.51% | Jan 11, 2021 |
Financial Forecast
Revenue This Year
2.24M
from 2.54M
Decreased by -11.65%
Revenue Next Year
1.84M
from 2.24M
Decreased by -18.18%
EPS This Year
-0.98
from -2.71
EPS Next Year
-0.74
from -0.98
Revenue Forecast
Revenue | 2024 | 2025 | 2026 |
---|---|---|---|
High | 2.3M | 1.9M | 2.4M |
Avg | 2.2M | 1.8M | 2.3M |
Low | 2.2M | 1.8M | 2.3M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | -9.1% | -15.8% | 31.5% |
Avg | -11.7% | -18.2% | 27.8% |
Low | -15.1% | -21.4% | 22.8% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -1.01 | -0.77 | -0.72 |
Avg | -0.98 | -0.74 | -0.70 |
Low | -0.94 | -0.72 | -0.68 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.